Cyclophosphamide
Select Advanced Solid Tumors
M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Select Advanced Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atezolizumab Immunocore Ltd | Phase 1/2 | CC |
Tebentafusp Immunocore Ltd | Phase 1/2 | CC |
Fludarabine M.D. Anderson Cancer Center | Phase 1/2 | CC |
Ksq-004Ex M.D. Anderson Cancer Center | Phase 1/2 | CC |
HLA- A*0201-RESTRICTED NY-ESO-1- AND LAGE-1A-SPECIFIC SOLUBLE TCR/ANTI-CD3 BISPECIFIC MOLECULE Immunocore Ltd | Phase 1/2 | CC |
View all 12 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →